BRIGHTON, England -- The risk of rare and opportunistic infections among patients with rheumatoid arthritis being treated with anti-tumor necrosis factor (TNF) therapy is small, researchers said here.
Despite numerous case reports of such infections, the absolute rate of serious infections among more than 10,000 patients on anti-TNF drugs was 1/1,000 years of patient follow-up, according to James B. Galloway, MD, of the University of Manchester in England, and colleagues.
To read the rest of the article:
http://www.medpagetoday.com/Rheumatology/Arthritis/25920